Mark R. Fahey

Monitoring Sedation Status Over Time in ICU Patients

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit

Natural products: An evolving role in future drug discovery

Adverse Drug Interactions in Anesthesia

Comparison of the Infusion Requirements and Recovery Profiles of Vecuronium and Cisatracurium 51W89 in Intensive Care Unit Patients

Anesthesiology

Natural products to drugs: natural product-derived compounds in clinical trials

Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure

Titration of Volatile Anesthetics Using Bispectral Index Facilitates Recovery after Ambulatory Anesthesia 

Clinical pharmacology of rocuronium (ORG 9426): Study of the time course of action, dose requirement, reversibility, and pharmacokinetics

European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support

The Pharmacokinetics of Vecuronium in Male and Female Patients

Sedation, Analgesia, and Paralysis in the Intensive Care Unit

Functional Disability 5 Years after Acute Respiratory Distress Syndrome

Paresis Acquired in the Intensive Care Unit<SUBTITLE>A Prospective Multicenter Study</SUBTITLE>

Development of ultra short‐acting muscle relaxant agents: History, research strategies, and challenges

New Neuromuscular Blocking Drugs

Persistent Paralysis in Critically Ill Patients after Long-Term Administration of Vecuronium

Herbal Medicines and Perioperative Care

Risk factors for the development of polyneuropathy and myopathy in critically ill patients

Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents

Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome

Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system

Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat

Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals

INTRAOPERATIVE USE OF MUSCLE RELAXANTS

Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors.

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient

COMPARISON OF THE NEUROMUSCULAR BLOCK INDUCED BY MIVACURIUM, SUXAMETHONIUM OR ATRACURIUM DURING NITROUS OXIDE-FENTANYL ANAESTHESIA

PIPECURONIUM AND PANCURONIUM: COMPARISON OF PHARMACOKINETICS AND DURATION OF ACTION †

Elimination of Atracurium in Humans

Pharmacokinetics and Pharmacodynamics of Atracurium in the Elderly

Vecuronium Inhibits Histamine N-Methyltransferase

EFFECT OF RENAL FAILURE ON LAUDANOSINE EXCRETION IN MAN

Metabolism of Isoflurane in Patients Receiving Isoniazid

The Dose-Response Relationship of Mivacurium Chloride in Humans during Nitrous Oxide-Fentanyl or Nitrous Oxide-Enflurane Anesthesia

Clinical Pharmacology of ORG NC45 (NorcuronTM)

The Influence of Renal Failure on the Pharmacokinetics and Duration of Action of Pipecuronium Bromide in Patients Anesthetized with Halothane and Nitrous Oxide

Metabolism of Isoflurane in Patients Receiving Isoniazid

Continuous Infusion of Vecuronium

Clinical Pharmacology of Vecuronium and Atracurium

PHARMACOKINETICS OF ORG NC45 (NORCURON) IN PATIENTS WITH AND WITHOUT RENAL FAILURE

The Pharmacokinetics and Pharmacodynamics of Atracurium in Patients with and without Renal Failure